Protocol Ledger

NCT04363801 · Phase II · TERMINATED

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Interventional Phase II clinical trial protocol NCT04363801 sponsored by Leap Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-29 Enrollment: 247 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04363801
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)247 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04363801
Protocol FieldVerified Registry Value
NCT IdentifierNCT04363801
Consolidated Lead SponsorLeap Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment247 participants (ACTUAL)
Registered Start Date2020-07-29
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04363801
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
University of ArizonaTucson, AZOpen Hospital Dossier ->
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI